Riverchase Wealth Management LLC Buys Shares of 4,919 AbbVie Inc. $ABBV

Riverchase Wealth Management LLC bought a new position in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, HoldingsChannel reports. The fund bought 4,919 shares of the company’s stock, valued at approximately $1,238,000. AbbVie accounts for about 0.6% of Riverchase Wealth Management LLC’s holdings, making the stock its 14th largest holding.

Other large investors also recently made changes to their positions in the company. Willner & Heller LLC grew its holdings in AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares in the last quarter. Bank of Jackson Hole Trust increased its position in AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after acquiring an additional 44 shares during the period. Eclectic Associates Inc. ADV raised its stake in AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after acquiring an additional 45 shares in the last quarter. Imprint Wealth LLC raised its stake in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares in the last quarter. Finally, Dogwood Wealth Management LLC boosted its position in AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after acquiring an additional 46 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Down 0.4%

Shares of NYSE:ABBV opened at $249.12 on Thursday. The firm has a fifty day moving average of $243.99 and a two-hundred day moving average of $225.73. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market capitalization of $440.14 billion, a P/E ratio of 70.37, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business posted $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. UBS Group raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Cantor Fitzgerald upped their price target on shares of AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Piper Sandler reiterated an “overweight” rating and issued a $298.00 price objective on shares of AbbVie in a report on Tuesday, June 23rd. HSBC reiterated a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Finally, Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $274.33.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canada supports UBRELVY reimbursement: Canada’s Drug Agency recommended reimbursement of UBRELVY for acute migraine treatment in adults. The decision could improve access and provide another growth opportunity for AbbVie’s neuroscience portfolio. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Positive Sentiment: BOTOX regulatory progress: AbbVie’s BOTOX filing helped attract investor attention, adding potential support for the aesthetics business and contributing to the stock’s recent strength. AbbVie Gains on Botox Filing
• Positive Sentiment: Immunology remains the key growth engine: Skyrizi and Rinvoq delivered strong sales, market-share gains and contributions from new indications, helping drive AbbVie’s second-quarter growth. Recent results also exceeded consensus estimates for earnings and revenue. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Neutral Sentiment: Pipeline updates provide optionality but limited immediate impact: AbbVie completed early testing of a venetoclax combination in high-risk myelodysplastic syndromes and completed a Phase 3 BOTOX jawline study. The updates advance development, but the reports did not provide definitive clinical results. AbbVie’s Venetoclax Combo in High-Risk MDS
• Neutral Sentiment: Analyst target increase reflects limited near-term upside: BNP Paribas Exane raised its price target from $218 to $247 while retaining a neutral rating, implying the shares were slightly above its revised valuation. Erste Group also modestly reduced its FY2027 EPS forecast but kept a Buy rating. BNP Paribas Exane AbbVie Price Target
• Negative Sentiment: Apogee acquisition increases leverage: Shareholders approved AbbVie’s Apogee Therapeutics acquisition, expanding the pipeline but requiring roughly $8 billion of additional debt. Investors focused on dividend safety may view the higher leverage and execution risk negatively. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.